TY - JOUR
TI - Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell
Lung Cancer: Incidence, Significance and Implications for Treatment
AU - Linardou, Helena
AU - Kotoula, Vassiliki
AU - Kouvatseas, George and
AU - Mountzios, Giannis
AU - Karavasilis, Vasilios
AU - Samantas, Epaminondas
AU - and Kalogera-Fountzila, Anna
AU - Televantou, Despina
AU - Papadopoulou,
AU - Kyriaki
AU - Mavropoulou, Xanthipi
AU - Daskalaki, Emily
AU - Zaramboukas,
AU - Thomas
AU - Efstratiou, Ioannis
AU - Lampaki, Sofia
AU - Rallis, Grigorios
AU - and Res, Eleni
AU - Syrigos, Konstantinos N.
AU - Kosmidis, Paris A. and
AU - Pectasides, Dimitrios
AU - Fountzilas, George
JO - Cancer Genomics & Proteomics
PY - 2019
VL - 16
TODO - 6
SP - 531-541
PB - INT INST ANTICANCER RESEARCH
SN - 1109-6535, 1790-6295
TODO - 10.21873/cgp.20155
TODO - KRAS; EGFR; mutations; platinum-based chemotherapy; NSCLC
TODO - Background/Aim: KRAS mutations are reported in 20-25% of non-small cell
lung cancer (NSCLC) and their prognostic role is unclear. We studied
KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods:
KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients
(diagnosed September 1998 -June 2013) and associated with
clinicopathological parameters. Outcome comparisons were performed in
288 patients receiving first line treatment. Results: Most patients were
male (78.6%), >60 years old (63.9%), current smokers (51.1%), with
adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in
10.7% and 16.6% of all histologies, respectively, and in 14.9% and
21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status
was an independent negative prognostic factor for overall survival (OS,
p=0.016). KRAS mutations conferred 80% increased risk of death in
patients receiving first-line treatment (p=0.002). Conclusion: The
presence of KRAS mutations is an independent negative prognosticator
among Greek NSCLC patients and an independent response predictor to
first line treatment.
ER -